The journey to develop drugs is long, time-consuming, and costly.Most drugs take years and billions of dollars before they hit the market.Traditional computations remain useful but have inadequacies to accurately reproduce molecular interactions and predict drug efficacy.Quantum computing represents a new tool to potentially revolutionize the challenges brought about by traditional computations in that it can more quickly and accurately solve several of these problems through applying the principles of quantum mechanics.This review examines the possibility of quantum computing to transform pharmaceutical research and drug development.The aim of this review is to give the reader an all-round perspective on the use of quantum computing in drug discovery, with its contributions to molecular modeling, drug-target interaction prediction, and pharmacological property optimization.It promises something new in the application of quantum algorithms to make up for the faults of classical methods used in pharmaceutical research.This review critically synthesizes a number of relevant studies that applied quantum computing capabilities to drug design.Particular attention is brought to quantum algorithms, including but not limited to VQE (Variational Quantum Eigensolver) and QAOA (Quantum Approximate Optimization Algorithm), in determining molecular structures in silico along with the capacity to predict chemical binding affinities.Secondly, the scope of the drugs-discovery application on the various platforms such as IBM Q versus Google Sycamore were compared with current classical computational approach.The quantum computer showed a lot of promise in the simulation of complicated molecular interactions faster than the classical counterparts.A lot of studies emphasize the accuracy quantum simulations have towards the prediction of drug-target binding mechanisms, and this makes the lead optimization process more efficient.However, with scalability and hardware issues, its application in the pharmaceutical research community is still yet to be wide-scale.Quantum computing promises to accelerate the drug development process by improving the speed and accuracy of molecular modeling and drug optimization.Although the field is still in its infancy, its integration into pharmaceutical research could lead to significant reductions in development time and cost.This review underlines the transformative potential of quantum computing and suggests future research directions for overcoming the current limitations and realizing its full potential in precision medicine.
The journey to develop drugs is long, time-consuming, and costly.Most drugs take years and billions of dollars before they hit the market.Traditional computations remain useful but have inadequacies to accurately reproduce molecular interactions and predict drug efficacy.Quantum computing represents a new tool to potentially revolutionize the challenges brought about by traditional computations in that it can more quickly and accurately solve several of these problems through applying the principles of quantum mechanics.This review examines the possibility of quantum computing to transform pharmaceutical research and drug development.The aim of this review is to give the reader an all-round perspective on the use of quantum computing in drug discovery, with its contributions to molecular modeling, drug-target interaction prediction, and pharmacological property optimization.It promises something new in the application of quantum algorithms to make up for the faults of classical methods used in pharmaceutical research.This review critically synthesizes a number of relevant studies that applied quantum computing capabilities to drug design.Particular attention is brought to quantum algorithms, including but not limited to VQE (Variational Quantum Eigensolver) and QAOA (Quantum Approximate Optimization Algorithm), in determining molecular structures in silico along with the capacity to predict chemical binding affinities.Secondly, the scope of the drugs-discovery application on the various platforms such as IBM Q versus Google Sycamore were compared with current classical computational approach.The quantum computer showed a lot of promise in the simulation of complicated molecular interactions faster than the classical counterparts.A lot of studies emphasize the accuracy quantum simulations have towards the prediction of drug-target binding mechanisms, and this makes the lead optimization process more efficient.However, with scalability and hardware issues, its application in the pharmaceutical research community is still yet to be wide-scale.Quantum computing promises to accelerate the drug development process by improving the speed and accuracy of molecular modeling and drug optimization.Although the field is still in its infancy, its integration into pharmaceutical research could lead to significant reductions in development time and cost.This review underlines the transformative potential of quantum computing and suggests future research directions for overcoming the current limitations and realizing its full potential in precision medicine.
INTRODUCTION: Quantum computing represents a transformative advancement in computational science, with applications in drug discovery, molecular interaction simulation, drug-target binding optimization, and the analysis of complex biological data at unprecedented speeds and accuracy. Quantum computing emerges as a powerful tool to accelerate the development of new therapeutics, drug design, and the simulation of complex chemical interactions, including personalized medicine strategies. The objective of this study is to explore the potential of quantum computing in drug discovery and development, highlighting its ability to reduce time and costs while accelerating the identification of promising drug candidates. METHODS: Quantum computing algorithms, such as Grover's algorithm and the Variational Quantum Eigensolver (VQE), are utilized to simulate molecular interactions of drugs and optimize drug design. In case studies, such as IBM's use of VQE for molecular simulations, these technologies demonstrate their effectiveness. RESULTS: Quantum computing has shown promise in addressing several technological barriers, such as lengthy development timelines and high costs. Additionally, demonstrated success in molecular simulations and solving challenges during the drug development process. However, challenges related to error rates, qubit coherence, and regulatory compliance remain. DISCUSSION: This study examines the applications of quantum computing in drug discovery, highlighting key techniques such as quantum simulation, quantum machine learning, and optimization algorithms. Quantum computing is crucial for interdisciplinary collaboration among quantum physicists, computational chemists, biologists, and pharmaceutical professionals, as it is essential to overcoming these obstacles and realizing the full potential of quantum technologies in medicine. CONCLUSION: Quantum computing holds great potential in drug discovery and development, offering accelerated, more accurate, and lower-cost research avenues, particularly in complex areas such as protein folding prediction and personalized medicine. This new paradigm has tremendous potential for guiding the future of pharmaceutical development and patient-focused medicine.
Drug development remains a complex, time-intensive, and costly process, with high failure rates in clinical trials. The advent of quantum computing presents promising opportunities to transform pharmaceutical research and development through enhanced molecular simulations and structure-based drug design. Quantum computing uses quantum mechanical phenomena like superposition and entanglement to process complex molecular interactions more efficiently than classical computers. The integration of quantum computing with machine learning algorithms has enabled more accurate predictions of drug-target interactions and improved virtual screening of compound libraries. Applications include structure-based drug design, molecular docking, lead optimization, and drug repurposing. Notable progress has been made through collaborations between pharmaceutical companies and quantum computing firms, demonstrating practical implementations in drug discovery workflows. However, several challenges persist, including hardware limitations, algorithmic maturity, skilled workforce gaps, and regulatory considerations. The combination of quantum computing with classical computing and machine learning approaches offers a hybrid framework that maximizes the strengths of each technology. As quantum computing technology advances, it is positioned to significantly impact pharmaceutical research and development, potentially reducing development timelines and improving success rates in drug discovery. This review explains the principles, current applications, integration, and limitations of quantum computing in drug development
The integration of quantum computing and artificial intelligence (AI), collectively termed Quantum AI, is revolutionizing the pharmaceutical industry by reshaping the paradigms of drug discovery and development. Traditional approaches to drug design are often limited by high costs, extensive timelines, and the computational intractability of simulating complex molecular interactions. Quantum computing offers exponential processing power, enabling the accurate modeling of quantum-level chemical phenomena that classical computers struggle to handle. Concurrently, AI contributes by enhancing data interpretation, prediction of molecular behaviors, and pattern recognition across large biological datasets. Together, Quantum AI enables faster identification of drug candidates, improved simulation of drug-target interactions, and early prediction of pharmacokinetics and toxicity. Key quantum algorithms, such as the Variational Quantum Eigensolver (VQE) and quantum-enhanced machine learning, have demonstrated potential to outperform conventional methods in quantum chemical calculations. Moreover, this synergy facilitates personalized medicine by integrating patient-specific data to optimize therapeutic outcomes. Despite current challenges related to hardware scalability, algorithm optimization, and ethical integration, the future trajectory of Quantum AI is poised to redefine pharmaceutical innovation. This review underscores the transformative capabilities of Quantum AI and its potential to usher in a new era of efficient, cost-effective, and precision-driven drug development.
Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.
This study identifies that new drugs are inherently complicated and require a lot of resources. These initiatives require years of financial investment, and the highly potent medicines that are produced were the final consequence. This study explores the potential uses of quantum computing to enhance molecular simulations and optimize drug prospect interactions. A comparative analysis between quantum and classical methodologies can be used to make a quantitative comparison. The results showed that VQE performs 37.8% more accurately than its classical predecessors, with a mean absolute error of 0.028 Hartree. Furthermore, the 86.7% success rate of QAOA in improving molecular structures would signify a significant performance improvement compared to traditional optimization methods. For VQE on quantum simulators, the average computing time is 8.4 minutes per molecule, which is 42.9% faster than for classical methods. Based on their better computational efficiency and ability to improve the accuracy of molecular property predictions, quantum algorithms appear to be a very promising tool for speeding up the drug discovery process. The results show that quantum machine learning has the potential to transform pharmaceutical research by advancing the development of new treatments.
The traditional drug discovery process is slow, resource-intensive, and often unsuccessful. This is mainly because regular computers find it hard to accurately model complex molecular interactions at the quantum level. This abstract suggests that Quantum Computing (QC) could change the game. It uses the principles of superposition and entanglement to transform pharmaceutical research. QC will provide a significant increase in computing power for quantum chemistry simulations. This will help researchers model the electronic structure of molecules and their exact behavior, including protein folding, binding affinities, and off-target effects, with great accuracy and speed. Algorithms like the Variational Quantum Eigensolver (VQE) are expected to uncover insights into drug-target interactions that we cannot currently obtain. This will greatly reduce the need for costly and lengthy physical experiments. Additionally, QC can improve virtual screening and support next-generation Quantum AI for faster analysis of genomic data and better optimization of drug candidates. Though the technology is still in its early stages, using QC could notably shorten development timelines and lower costs. This will enable the discovery of more targeted and effective drugs, leading to significant progress in treating complex diseases and a new era of precise, personalized medicine. The shift will require ongoing investment in reliable quantum hardware and specialized quantum algorithms.